Cognition Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Cognition Therapeutics, Inc. (CGTX) reported Other Comprehensive Income (Loss), Net of Tax of $3.75 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-03-26
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was -$1.00K.
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was $4.00K, a 300.00% increase year-over-year.
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$1.00K.
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$3.00K.
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $3.75M, a 93600.00% increase from fiscal 2023.
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $4.00K.
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$1.00K.
- Cognition Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2021 was -$11.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $3.75M 10-K · filed 2026-03-26 | |||
| 2023-12-31 | $4.00K 10-K · filed 2025-03-20 | |||
| 2023-06-30 | -$1.00K 10-Q · filed 2024-11-13 | $3.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $4.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | -$1.00K 10-K · filed 2024-03-26 | |||
| 2022-09-30 | -$1.00K 10-Q · filed 2023-11-02 | -$4.00K derived: sum of 2 quarters · filed 2023-11-02 | -$3.00K derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$3.00K 10-Q · filed 2023-11-02 | -$2.00K derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $1.00K 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | -$11.00K 10-K · filed 2023-03-23 | |||
| 2021-09-30 | -$3.00K 10-Q · filed 2022-11-14 | -$4.00K derived: sum of 2 quarters · filed 2022-11-14 | -$9.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$1.00K 10-Q · filed 2022-11-14 | -$6.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | -$5.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | -$2.00K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $18.00K 10-Q · filed 2021-11-17 | $74.00K derived: sum of 2 quarters · filed 2021-11-17 | -$40.00K derived: sum of 3 quarters · filed 2021-11-17 | |
| 2020-06-30 | $56.00K 10-Q · filed 2021-11-17 | -$58.00K derived: sum of 2 quarters · filed 2021-11-17 | ||
| 2020-03-31 | -$114.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |